Analysis and Commentary STEVEN GROSSMAN 1/12/24 Analysis and Commentary STEVEN GROSSMAN 1/12/24 What Happens to FDA If There is a Shutdown Read More Analysis and Commentary STEVEN GROSSMAN 1/5/24 Analysis and Commentary STEVEN GROSSMAN 1/5/24 No Predetermined Outcome in Budget Negotiations Read More Analysis and Commentary STEVEN GROSSMAN 12/15/23 Analysis and Commentary STEVEN GROSSMAN 12/15/23 Uncertainty, As Well As Risk to FDA in FY24 Appropriations Process Read More Analysis and Commentary STEVEN GROSSMAN 12/8/23 Analysis and Commentary STEVEN GROSSMAN 12/8/23 FDA Funding At Risk In Current Budget Negotiations Read More Analysis and Commentary STEVEN GROSSMAN 12/1/23 Analysis and Commentary STEVEN GROSSMAN 12/1/23 What Must End, Will End. But When and How? Read More Analysis and Commentary STEVEN GROSSMAN 11/17/23 Analysis and Commentary STEVEN GROSSMAN 11/17/23 “Nothing Resolved. Everything Still on the Table.” Read More Analysis and Commentary STEVEN GROSSMAN 11/15/23 Analysis and Commentary STEVEN GROSSMAN 11/15/23 Shutdown Threats: Second Verse Same as the First; FDA Budget Still at Risk Read More Analysis and Commentary STEVEN GROSSMAN 11/3/23 Analysis and Commentary STEVEN GROSSMAN 11/3/23 Level-Funding in FY 24: A Substantial Risk to FDA Priorities Read More Analysis and Commentary STEVEN GROSSMAN 10/27/23 Analysis and Commentary STEVEN GROSSMAN 10/27/23 Concrete Progress; Still A Long Way from Settling FDA’s FY 24 Funding Read More Analysis and Commentary STEVEN GROSSMAN 10/13/23 Analysis and Commentary STEVEN GROSSMAN 10/13/23 FY 24 Appropriations: House Options Limited Regardless of Who Becomes Speaker Read More Analysis and Commentary STEVEN GROSSMAN 10/6/23 Analysis and Commentary STEVEN GROSSMAN 10/6/23 Lots to Learn from a Near-Shutdown Experience Read More Analysis and Commentary STEVEN GROSSMAN 9/29/23 Analysis and Commentary STEVEN GROSSMAN 9/29/23 More Q&A As the Shutdown Becomes Inevitable Read More Analysis and Commentary STEVEN GROSSMAN 9/22/23 Analysis and Commentary STEVEN GROSSMAN 9/22/23 Shutdown Becomes a Near-Certainty: Your Questions Answered Read More Analysis and Commentary STEVEN GROSSMAN 9/15/23 Analysis and Commentary STEVEN GROSSMAN 9/15/23 Q&A: Shutdowns at FDA Are Complicated Part 2 Read More Analysis and Commentary STEVEN GROSSMAN 9/8/23 Analysis and Commentary STEVEN GROSSMAN 9/8/23 Q&A: Shutdowns at FDA Are Complicated Read More Analysis and Commentary STEVEN GROSSMAN 9/1/23 Analysis and Commentary STEVEN GROSSMAN 9/1/23 Product Shortages’ Prominent Place on FDA’s Agenda Read More Analysis and Commentary STEVEN GROSSMAN 8/25/23 Analysis and Commentary STEVEN GROSSMAN 8/25/23 Commissioner Califf Talks About AI Read More Analysis and Commentary STEVEN GROSSMAN 8/4/23 Analysis and Commentary STEVEN GROSSMAN 8/4/23 FDA Funding Judged in Absolute and Relative Terms Read More Analysis and Commentary STEVEN GROSSMAN 7/28/23 Analysis and Commentary STEVEN GROSSMAN 7/28/23 FDA, Appropriations, and Chaos: The Risk of a Perfect Storm Read More Analysis and Commentary STEVEN GROSSMAN 7/21/23 Analysis and Commentary STEVEN GROSSMAN 7/21/23 “FDA Brings Good Things to Life” Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 1/12/24 Analysis and Commentary STEVEN GROSSMAN 1/12/24 What Happens to FDA If There is a Shutdown Read More
Analysis and Commentary STEVEN GROSSMAN 1/5/24 Analysis and Commentary STEVEN GROSSMAN 1/5/24 No Predetermined Outcome in Budget Negotiations Read More
Analysis and Commentary STEVEN GROSSMAN 12/15/23 Analysis and Commentary STEVEN GROSSMAN 12/15/23 Uncertainty, As Well As Risk to FDA in FY24 Appropriations Process Read More
Analysis and Commentary STEVEN GROSSMAN 12/8/23 Analysis and Commentary STEVEN GROSSMAN 12/8/23 FDA Funding At Risk In Current Budget Negotiations Read More
Analysis and Commentary STEVEN GROSSMAN 12/1/23 Analysis and Commentary STEVEN GROSSMAN 12/1/23 What Must End, Will End. But When and How? Read More
Analysis and Commentary STEVEN GROSSMAN 11/17/23 Analysis and Commentary STEVEN GROSSMAN 11/17/23 “Nothing Resolved. Everything Still on the Table.” Read More
Analysis and Commentary STEVEN GROSSMAN 11/15/23 Analysis and Commentary STEVEN GROSSMAN 11/15/23 Shutdown Threats: Second Verse Same as the First; FDA Budget Still at Risk Read More
Analysis and Commentary STEVEN GROSSMAN 11/3/23 Analysis and Commentary STEVEN GROSSMAN 11/3/23 Level-Funding in FY 24: A Substantial Risk to FDA Priorities Read More
Analysis and Commentary STEVEN GROSSMAN 10/27/23 Analysis and Commentary STEVEN GROSSMAN 10/27/23 Concrete Progress; Still A Long Way from Settling FDA’s FY 24 Funding Read More
Analysis and Commentary STEVEN GROSSMAN 10/13/23 Analysis and Commentary STEVEN GROSSMAN 10/13/23 FY 24 Appropriations: House Options Limited Regardless of Who Becomes Speaker Read More
Analysis and Commentary STEVEN GROSSMAN 10/6/23 Analysis and Commentary STEVEN GROSSMAN 10/6/23 Lots to Learn from a Near-Shutdown Experience Read More
Analysis and Commentary STEVEN GROSSMAN 9/29/23 Analysis and Commentary STEVEN GROSSMAN 9/29/23 More Q&A As the Shutdown Becomes Inevitable Read More
Analysis and Commentary STEVEN GROSSMAN 9/22/23 Analysis and Commentary STEVEN GROSSMAN 9/22/23 Shutdown Becomes a Near-Certainty: Your Questions Answered Read More
Analysis and Commentary STEVEN GROSSMAN 9/15/23 Analysis and Commentary STEVEN GROSSMAN 9/15/23 Q&A: Shutdowns at FDA Are Complicated Part 2 Read More
Analysis and Commentary STEVEN GROSSMAN 9/8/23 Analysis and Commentary STEVEN GROSSMAN 9/8/23 Q&A: Shutdowns at FDA Are Complicated Read More
Analysis and Commentary STEVEN GROSSMAN 9/1/23 Analysis and Commentary STEVEN GROSSMAN 9/1/23 Product Shortages’ Prominent Place on FDA’s Agenda Read More
Analysis and Commentary STEVEN GROSSMAN 8/25/23 Analysis and Commentary STEVEN GROSSMAN 8/25/23 Commissioner Califf Talks About AI Read More
Analysis and Commentary STEVEN GROSSMAN 8/4/23 Analysis and Commentary STEVEN GROSSMAN 8/4/23 FDA Funding Judged in Absolute and Relative Terms Read More
Analysis and Commentary STEVEN GROSSMAN 7/28/23 Analysis and Commentary STEVEN GROSSMAN 7/28/23 FDA, Appropriations, and Chaos: The Risk of a Perfect Storm Read More
Analysis and Commentary STEVEN GROSSMAN 7/21/23 Analysis and Commentary STEVEN GROSSMAN 7/21/23 “FDA Brings Good Things to Life” Read More
